drugset / Trial / NCT06692361

Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder

NCT06692361

RandomizedParallel-groupTriple-blindTreatment

Summary

This study aimed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in patients with major depressive disorder (MDD) who exhibit suboptimal early response to antidepressant treatment. Additionally, it sought to investigate the impact of FMT on biological indicators, including intestinal microbiota and metabolites, in individuals with MDD

Timeline

Start
2025-01-01
Primary completion
2026-06
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject FMT Unknown 1 g Oral
Background Escitalopram Small molecule